Sanofi signs on to sell Vivus ED med in emerging markets; GSK's quadrivalent flu vaccine impresses in NEJM study;

@FiercePharma: India's Lupin already launched its copies of Eli Lilly's $5B antidepressant, Cymbalta, in U.S. Half-dozen companies got FDA nod. Poor Lilly. | Follow @FiercePharma

@EricPFierce: Merck KGaA's Allergopharma unit building a €40M plant near Hamburg that will make allergy meds for China. Release | Follow @EricPFierce

@CarlyHFierce: Here come the Cymbalta copies. FDA approves generics from Teva, Sun, Dr. Reddy's, Lupin and others. Release | Follow @CarlyHFierce

> Vivus ($VVUS) has found another marketing partner for its erectile dysfunction drug Stendra: Sanofi ($SNY), which will promote the drug in several emerging markets, including Russia and Turkey. Release

> GlaxoSmithKline's ($GSK) FluLaval quadrivalent flu vaccine cut flu cases in small children by 55% and slashed the risk of moderate-to-serious illness by 73%, a New England Journal of Medicine study found. Release | Report

> Roche's ($RHHBY) cancer fighter Herceptin (trastuzumab) is poised for a big boost in China in HER2-positive gastric cancer, Decision Resources found, with one key reimbursement decision on its way. Report

> Novartis ($NVS) said its myelofibrosis treatment Jakavi (ruxolitinib) helped study patients live longer than those treated with placebo or conventional therapy. Report

> GlaxoSmithKline said stockists and retailers in India have resumed purchasing its products after a pricing-related protest that began in September. Report

> Warner Chilcott inked a patent settlement with Zydus Pharmaceuticals that will allow the India-based generics maker to launch a generic version of the colitis treatment Asacol HD beginning Nov. 15, 2015. Report

> The German pharma wholesaler Celesio said its board had recommended shareholder approval for an $8.3 billion takeover by rival McKesson ($MCK). Report

Medical Device News

@FierceMedDev: Avinger draws new financing to back testing of light-enhanced PAD catheter. Article | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical won a CE mark for a larger size of its Portico heart valve, adding to a now-crowded competition. More | Follow @MarkHFierce

@MichaelGFierce: AdvaMed, MDMA commend congressional budget deal as vote approaches. Story | Follow @MichaelGFierce

@GalenMoore: Senesco Announces up to $25.2 Million Equity Financing. Release | Follow @GalenMoore

> Boston Scientific's Watchman stroke-fighting device wins overwhelming FDA panel support. Piece

> T2 brings on 2 Hologic vets as work continues on Candida assay ramp-up. News

Biotech News

@FierceBiotech: In January, Levin dumped Teva's immunotherapy program. Now, checkpoint receptor drugs are all the rage. More | Follow @FierceBiotech

@JohnCFierce: Galderma Labs axing staff in U.S. shakeup after president exits (gee, the rumors were true). News | Follow @JohnCFierce

@DamianFierce: Imagine being the Novartis worker who picked up Retrophin's call. "Hey, so, remember Syntocinon?" | Follow @DamianFierce

@EmilyMFierce: Congressional budget deal would restore NIH sequester cuts. Coverage | Follow @EmilyMFierce

> FDA panel throws dirt on Bristol-Myers' orphan drug metreleptin. Story

> ImmunoCellular tanks after cancer vaccine flops on key endpoint in PhII. Article

> Roche signs Prothena for up to $600M in Parkinson's drug development deal. More

Vaccines News

> GSK shares data from pivotal PhIII trial of quadrivalent flu vaccine. Story

> Novartis awaits pivotal Bexsero decisions in Canada and Europe. Piece

> Genocea begins a PhI trial of its rival to Pfizer's Prevnar. News

> AstraZeneca eyes 2014 EU launch for 4-in-1 flu vaccine after winning approval. More

> Pentagon tasks Pfizer with radically rethinking vaccine development. Article

> Lundbeck teams with Otsuka on Alzheimer's vaccine development. Item

Pharma Manufacturing News

> ScinoPharma's $113 million China API plant ready to go. News

> Merck KGaA targets China with a planned, €40M allergy plant. More

> FDA stationing 10 new drug inspectors in China. Story

> GSK's new manufacturing investments in the U.K. now pass $1 billion. Article

> Cardinal, CVS JV creates more upheaval in U.S. drug supply chain. Piece

> FDA warns NJ lotion maker: Your water does not meet specs. Item

And Finally ... Cancer deaths around the world rose to 8.2 million last year, including a disturbing rise in deaths from breast cancer. Report

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

The countdown to the FDA's first coronavirus vaccine hearing has begun, and new agency documents outline an agenda for the Thursday confab.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.